



IN THE CLAIMS:

Claims 1-33 (Cancelled)

34. (Currently amended) A method of anti-platelet therapy or prophylaxis comprising administering to a subject in need thereof a composition comprising an effective amount of a procyanidin oligomer comprising from 2 to 18 monomeric units of the following formula:




38. (Previously added) The method of claim 34, wherein the procyanidin oligomer comprises 2 monomeric units:
39. (Currently amended) ~~The method of claim 34, wherein~~ A method of anti-platelet therapy or prophylaxis comprising administering to a subject in need thereof a composition comprising an effective amount of a the procyanidin oligomer has having the formula:



and n is 0 to 16.

40. (Currently amended) ~~The method of claim 34, wherein the~~ A method of anti-platelet

therapy or prophylaxis comprising administering to a subject in need thereof a composition comprising an effective amount of a procyanidin oligomer ~~has~~ having the formula:



wherein A and B are independently oligomers having 1 to 15 monomeric units, and the total number of monomeric units in the procyanidin oligomer is 3 to 18.

41. (Previously added) The method of claim 34, wherein the subject is a human.
42. (Previously added) The method of claim 35, wherein the subject is a human.

43. (Previously added) The method of claim 36, wherein the subject is a human.
44. (Previously added) The method of claim 37, wherein the subject is a human.
45. (Previously added) The method of claim 38, wherein the subject is a human.
46. (Previously added) The method of claim 39, wherein the subject is a human.
47. (Previously added) The method of claim 40, wherein the subject is a human.
48. (Previously added) The method of claim 41, wherein the human suffers from atherosclerosis.
49. (Previously added) The method of claim 42, wherein the human suffers from atherosclerosis.
50. (Previously added) The method of claim 43, wherein the human suffers from atherosclerosis.
51. (Previously added) The method of claim 44, wherein the human suffers from atherosclerosis.
52. (Previously added) The method of claim 45, wherein the human suffers from atherosclerosis.
53. (Previously added) The method of claim 46, wherein the human suffers from atherosclerosis.

54. (Previously added) The method of claim 47, wherein the human suffers from atherosclerosis.
55. (Previously added) The method of claim 41, wherein the human is at risk of atherosclerosis.
56. (Previously added) The method of claim 42, wherein the human is at risk of atherosclerosis.
57. (Previously added) The method of claim 43, wherein the human is at risk of atherosclerosis.
58. (Previously added) The method of claim 44, wherein the human is at risk of atherosclerosis.
59. (Previously added) The method of claim 45, wherein the human is at risk of atherosclerosis.
60. (Previously added) The method of claim 46, wherein the human is at risk of atherosclerosis.
61. (Previously added) The method of claim 47, wherein the human is at risk of atherosclerosis.
62. (Currently amended) The method of claim 34, wherein the ~~procyanidin oligomer is administered with a pharmaceutically acceptable carrier~~ composition is a pharmaceutical composition.
63. (Currently amended) The method of claim 34, wherein the ~~composition~~ procyanidin

oligomer is in a food composition.

64. (Currently amended) The method of claim 34, wherein the composition ~~precyanidin~~ oligomer is in a dietary supplement composition.
65. (Currently amended) The method of claim 36, wherein the ~~precyanidin oligomer is administered with a pharmaceutically acceptable carrier~~ composition is a pharmaceutical composition.
66. (Currently amended) The method of claim 36, wherein the composition ~~precyanidin~~ oligomer is in a food composition.
67. (Currently amended) The method of claim 36, wherein the composition ~~precyanidin~~ oligomer is in a dietary supplement composition.
68. (Currently amended) The method of claim 37, wherein the ~~precyanidin oligomer is administered with a pharmaceutically acceptable carrier~~ composition is a pharmaceutical composition.
69. (Currently amended) The method of claim 37, wherein the composition ~~precyanidin~~ oligomer is in a food composition.
70. (Currently amended) The method of claim 37, wherein the composition ~~precyanidin~~ oligomer is in a dietary supplement composition.
71. (Currently amended) The method of claim 38, wherein the ~~precyanidin oligomer is administered with a pharmaceutically acceptable carrier~~ composition is a pharmaceutical composition.

72. (Currently amended) The method of claim 38, wherein the composition ~~precyanidin~~ oligomer is in a food composition.
73. (Currently amended) The method of claim 38, wherein the composition ~~precyanidin~~ oligomer is in a dietary supplement composition.
74. (new) The method of claim 39, wherein the composition is a pharmaceutical composition.
75. (new) The method of claim 39, wherein the composition is a food composition.
76. (new) The method of claim 39, wherein the composition is a dietary supplement composition.
77. (new) The method of claim 40, wherein the composition is a pharmaceutical composition.
78. (new) The method of claim 40, wherein the composition is a food composition.
79. (new) The method of claim 40, wherein the composition is a dietary supplement composition.
80. (new) The method of claim 34, wherein the derivative is a glycosylated procyanidin oligomer.